Phase 4
Completed N=26
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
Source: ClinicalTrials.gov NCT00414765 ↗Enrolled (actual)
26
Serious AEs
26.9%
Results posted
Jun 2021
Primary outcomePrimary: Change in the Area Under the Concentration-Time Curve (AUC) From 0 to 8 Hours (AUC0-8) of Aldesleukin After One Cycle of Therapy — 60359.9; 173127.7; -22171.6 hour times picograms per mL(h × pg/mL)
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in the Area Under the Concentration-Time Curve (AUC) From 0 to 8 Hours (AUC0-8) of Aldesleukin After One Cycle of Therapy |
60359.9; 173127.7; -22171.6 | — |
Eligibility Criteria
Inclusion criteria
- Performance Status Eastern Cooperative Oncology Group: 0 or 1.
- Adequate organ function.
Exclusion criteria
- Pregnancy or lactation.
- Prior treatment with any form of IL-2.
- Organ transplant. Other protocol-defined inclusion/exclusion criteria may apply
Data sourced from ClinicalTrials.gov (NCT00414765). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.